Know how to PI3K 'em:

Phosphoinositide 3-kinase (PI3K)-targeted agents are now approved for a host of heme malignancies and even some metastatic breast cancers so it’s worth noting that 30% of patients develop a rash, usually a very nonspecific maculopapular rash but sometime acneiform, that typically responds to antihistamines. | Jfri, JAMA Oncol 2022